Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Diagnostic radiopharmaceuticals | 1 |
Therapeutic radiopharmaceuticals | 1 |
Small molecule drug | 1 |
Radiolabeled antibody | 1 |
Top 5 Target | Count |
---|---|
CEACAM6(Carcinoembryonic antigen related cell adhesion molecule 6) | 1 |
Target- |
Mechanism Ionising radiation emitters |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date18 Jun 2015 |
Target |
Mechanism CEACAM6 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date14 Feb 1997 |
Target |
Mechanism TSPO modulators |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date29 Jan 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
99mTc-Sulesomab ( CEACAM6 ) | Osteomyelitis More | Approved |
Lutetium (177 Lu) Chloride | Diagnostic agents More | Approved |
11C-PBR-170 ( TSPO ) | - | Pending |